What is SimulStat?
Founded in 2001, SimulStat operates as a specialized provider of staffing solutions tailored for the biostatistics and epidemiology sectors. The company bridges the talent gap in the pharmaceutical industry by offering highly skilled biometric professionals through flexible engagement models, including staff augmentation, functional service provision, and comprehensive project outsourcing. Their long-standing track record demonstrates a deep understanding of the regulatory and technical requirements inherent in drug development and clinical trial management, making them a vital partner for life sciences firms navigating complex data landscapes.
How much funding has SimulStat raised?
SimulStat has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in SimulStat
PPP
Public-Private Partnership
What's next for SimulStat?
With this major enterprise-level funding, SimulStat is poised to scale its operational capacity to meet the accelerating demand for specialized data expertise in global clinical trials. The strategic deployment of this capital will likely focus on enhancing their talent acquisition infrastructure and expanding their service offerings to include more advanced real-world evidence analytics. As the pharmaceutical industry continues to prioritize data-driven decision-making, SimulStat's ability to provide high-caliber biometric talent will be a key driver of their long-term growth trajectory and competitive advantage in the professional services market.
See full SimulStat company page
